Browse > Article

Vasorelaxant properties of cyclic nucleotide phosphodiesterase inhibitors in rat aorta  

Kang, Hyung-sub (Bio-Safety Research Institute, Chonbuk National University)
Choi, Cheol-ho (Bio-Safety Research Institute, Chonbuk National University)
Kim, Jin-shang (Bio-Safety Research Institute, Chonbuk National University)
Publication Information
Korean Journal of Veterinary Research / v.43, no.4, 2003 , pp. 615-624 More about this Journal
Abstract
Vascular smooth muscle relaxation is modulated by an increase in cGMP subsequent to nitric oxide (NO) production by endothelial cells. The effects of cAMP and cGMP phosphodiesterase (PDE) inhibitors were investigated in phenylephrine-precontracted rat aorta rings by using the specific inhibitors of PDE I, III, IV and V as relaxing agents (calmodulin-activated PDE inhibitors, IBMX and $W_7$, type I; cAMP-specific PDE inhibitors, milrinone, type IV; Ro 20-1724, type III and cGMP-specific PDE inhibitor, zaprinast, type V). All the PDE inhibitors produced a concentration-dependent relaxation in the ring with intact endothelium (+E). Except for milrinone, all the PDE inhibitors-induced relaxations were inhibited by removal of extracellular $Ca^{2+}$, $N^G$-nitro-L-arginine, $N^G$-nitro-L-arginine methyl ester, methylene blue (MS) or nifedipine. The specific PDE I and PDE IV inhibitors both produced endothelium-independent relaxations which were inhibited by MS in -E rings. However, zaprinast had no effect in -E rings. Except for milrinone, sodium nitroprusside (a NO donor)-induced relaxation was significantly augmented by all PDE inhibitors in +E rings. The results suggest that I) the vasorelaxant properties of IBMX, $W_7$, Ro 20-1724 and zaprinast are dependent on endothelium or on interaction with $Ca^{2+}$ regulation, 2) each PDE is differently distributed in vascular tissues (endothelial and smooth muscle cells), 3) the vasodilations of PDE inhibitors are due to the increase of cAMP and cGMP formation through inhibition of cAMP- and cGMP-PDE and 4) the vasodilation action of milrinone does not involve in endothelial-cyclic nucleotide system.
Keywords
Phosphodiesterase inhibitors; endothelium; cGMP; relaxation; aorta;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Beavo, J. A. and Reifsnyder, D. H. Primary sequence of cyclic nucteotide phosphodiesterase isozymes and the design of selective inhibitors. Trencls Pharmacol Sci. 1990, 11. 150-155
2 Carvajal, J. A., Germain, A. M., Huidobro-Toro, J. P. and Weiner, C. P. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiul. 2000, 184, 409-420
3 Karaki, H., Ozaki, H., Hori, M., Mitsui-Saito, M.,Amano, K., Harada, K., Miyamoto, S., Nakazawa,H, Won, K. J. and Sato, K. Calcium movements, distribution, and functions in smooth muscle. Phannacol Rev. 1997, 42, 157-230
4 Lincoln, T. M. and Comwell, T. L. Intracellular cyclic GMP receptor proteins. FASEB J, 1993, 7, 328-338
5 Lugnier, C., Keravis, T. and Eckly-Michel, A. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel. J Physiol Pharmacol, 1999, 50. 639-652
6 Nakamura, T., Houchi, H., Minami, A., Sakamoto, S., Tsuchiya, K., Niwa, Y., Minakuchi, K. and Nakaya, Y. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci. 2001, 69, 1709-1715
7 Perez-Vizcaino, E, Cogolludo, A. L., Zaragoza- Amaez, E, Fajardo, S., Ibarra, M., Lopez-Lopez, J. G. and Tamargo, J. Vasodilator effects of sodium nitroprusside, levcromakalim and their combination in isolated rat. Br. J. Pharmacol, 1999, 128, 1419-1426
8 Shiraishi, Y., Kanmura, Y. and Itoh, T. Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [$Ca^2^+$]i and force in middle cerebral artery of the rabbit. Br. J. Pharmacol. 1998, 123, 869-878
9 Souness, J. E., Diocee, B. K., Martin, W. and Moodie, S. A. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells. Biochem. J. 1990, 266, 127-132
10 Strosberg, A. D. Structure, function, and regulation of adrenergic receptors. Protein Sci. 1993, 2, 1198-1209
11 Taggart, M. J., Menice, C. B., Morgan, K. G. and Wray, S. Effect of metabolic inhibition on intracellular $Ca^2^+$, Phosphorylation of myosin regulatory light chain and force in rat smooth muscle. J. Physiol. 1997, 499, 485-496
12 Tejerina, T., Sesin, J., Delgado, C. and Tamargo, J. Effect of milrinone on contractility and 45Ca movements in the isolated rabbit aorta. Eur. J. Pharmacol. 1988, 148, 239-246
13 Tomkinson, A. and Raeburn, D. The effect of isoenzyme-selective PDE inhibitors on rnethacholine- induced contraction of guinea-pig and rat ileum. Br. J. Pharmacol. 1996, 118, 2131-2139
14 Weishaar, R. E., Burrows, S. D., Kobylarz, D. C., Quade, M. M. and Evans, D. B. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets, Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem. Pharmacol. 1986, 35, 787-800
15 Lugnier, C., Keravis, T., Le Bec, A., Pauvert, O., Proteau, S. and Rinissuau, E. Characterization of cyclic nucleotide phosphodiesterase isutbrms associated to isolated cardiac nuclei. Biochim Biophys Acta. 1999, 1472, 431-446
16 Yu, S. M., Cheng, Z. J. and Kuo, S. C. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor. Eur. J. Pharmacol. 1995, 280, 69-77
17 Silver, P. J. Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase. Am. J. Cardiol. 1989, 63, 2A-8A
18 Shiraski, Y. and Su, C. Endothelium removal augments vasodilation by sodium nitroprusside and sodium nitrite. Eur. J. Pharmacol. 1985, 114, 93-96
19 Lugnier, C., Schoeffter, P., Le Bec, A., Strouthou, E. and Stoclet, J. C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol, 1986, 35, 1743-1751
20 Medina, P., Segarra, G., Vila, J. M., Domenech, C., Martinez-Leon, J. B. and Lluch, S. Effects of sildenafil on human penile blood vessels. Urology. 2000, 56. 539-543
21 Taira, N. Inotropic agents: new positive inotropic agents and their mechanism of action, In: Rand, MJ, Raper, C. (EDs.), Pharmacology, pp. 477-480, Elsevier, Amsterdam. 1987
22 Beavo, J. A. Cyclic nucleotide phosphodiesterases: func-tional implications of multiple isofumis. Physiol Rev. 1995, 75, 725-748
23 Inada, H., Shindo, H., Tawata, M. and Onaya, T. Cilostazol, a cyclic AMP phosphodiesterase inhibitor, stimulates nitric oxide production and sodium potassium adenosine triphosphatase activity in SH-SY5Y human neuroblastoma cells. Life Sci. 1999, 65, 1413-1422
24 Lincoln, T. M. Eftects of nitroprusside and 8-bromo-cyclic GMP on the contractile activity of the rat aorta. J Pharmacol Exp Ther, 1983. 224, 100-107
25 Lugnier, C. and Komas, N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J. 1993, 14(Suppl I), 141-148
26 Parson, W. J., Ramkumar. V. and Stiles, G. L. Isobutyl methylxanthine stimulates adenylate-cyclase by blocking the inhibitory regulatory protein Gi. Mol. Phannacol. 1988, 34, 37-41
27 Lincoln, T. M., Komalavilas. P. and Cornwell, T. L. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension, 1994, 23(6 Pt 2), 1141-1147
28 Medina, P., Segarra, G., Martinez-Leon, J. B., Vila, J. M., Aldasoro, M., Otero, E. and Lluch, S. Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. Ann. Thorac. Surg. 2000, 70, 1327-1331
29 Polson, J. B. and Strada, S. J. Cyclic nucleotide phos-phodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 403-427
30 Delpy, E., Coste, H. and Gouville, A. C. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br. J Pharmacol, 1996. 119, 471-478
31 van der Zypp, A., Rechtman, M. and Majewski, H. The role of cyclic nucleotides and calcium in the relaxation produced by amnnone in rat aorta. Gen. Pharmacol. 2000, 34, 245-253
32 Honerjager, P. Pharmacology of positive inotropic phos-phodiesterase Ill inhibitors. Eur Heart J, 1989, 10(Suppl C), 25-31
33 Komas, N., Lugnier, C. and Stoclet, J. C. Endothelium- dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br. J Pharmacol, 1991, 104, 495-503
34 Martin, W., Furchgott, R. E, ViBani, G. M. and Jothianandan, D. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1986, 237. 539-547
35 Ito, S., Suzuki, S. and Itoh, T. ElTects of a water-soluble forskolin derivative (NKH477) and a membrane-permeable cyclic AMP analogue on noradrenaline-induced$Ca^2^+$ mobilization in smooth muscle of rabbit mesenteric artery. Br. J Pharrnacol. 1993. 110, 1117-1125
36 Rapoport, R. M. Cyclic guanosine monophosphate inhibi-tion of contraction may be mediated through inhibition of phosphatidylinositol hydrolysis in rat aorta. Circ. Res. 1986, 58, 407-410
37 Harrison, S. A., Chang, M. L. and Beavo, J. A. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs. Circulation, 1986, 73(3 Pt 2), III 109-116
38 Prigent, A. E, Fougier, S., Nemoz, G., Anker, G., Pacheco, H., Lugnier, C., Lebec, A. and Stoclet, J. C. Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta, Separation and inhibition by selective reference phosphodiesterase inhibitoK. Biochem. Phannacol. 1988, 37, 3671-3681
39 Nicholson, C. D., Challiss, R. A. and Shahid, M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 1991, 12, 19-27
40 Gray, D. W. and Marshall, I. Novel signal transduction pathway mediating endothelium-dependent beta-adre-noceptor vasorelaxation in rat thoracic aorta. Br. J Phannacol, 1992, 107, 684-690